TRIAL DATA
Adding Chemotherapy to Immunotherapy May Extend Survival in MSI-H Metastatic CRCThe phase III NRG-GI004/SWOG S1610 COMMIT trial found that combining mFOLFOX6, bevacizumab, and atezolizumab may prolong progression-free survival over atezolizumab alone in first-line treatment of mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. (The ASCO Post)